KDx Diagnostics gets FDA breakthrough device status for URO17 bladder cancer recurrence test
The test is said to apply a novel cancer marker to improve the accuracy and sensitivity of non-invasive…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Jan 20
The test is said to apply a novel cancer marker to improve the accuracy and sensitivity of non-invasive…
08 Jan 20
Sebia will develop the test and act as worldwide supplier
08 Jan 20
Mobidiag is harnessing the power of its Novodiag platform to develop a fast, simple and reliable syndromic assay…
The Phase II contract follows a Phase I contract that supported development of initial proof-of-concept data for PathMAP…
08 Jan 20
IceCure Medical is an Israeli medical device company that develops and markets an advanced liquid-nitrogen-based cryoablation therapy for…
08 Jan 20
Oncologists can use the NeXT Dx test to identify potential therapies and clinical trial options for cancer patients
03 Jan 20
The companies have decided to terminate the agreement due to lengthy regulatory approval process and continued uncertainty of…
02 Jan 20
Hardy Diagnostics introduces HealthLink Universal Transport Medium for collection, transport, maintenance and long-term freeze storage of clinical specimens
31 Dec 19
The FDA approval allows commercialisation of its RD SET sensors, with improved performance specifications, for all patient populations…
27 Dec 19
The acquisition enables Astellas to gain Xyphos' proprietary Advanced Cellular Control through Engineered Ligands (ACCEL) technology platform